帯状疱疹治療薬の市場規模、シェア、成長分析、診断別、治療と予防別、投与経路別、エンドユーザー別、地域別 - 産業予測 2025年～2032年

帯状疱疹治療薬の世界市場規模は2023年に22億米ドルと評価され、2024年の24億2,000万米ドルから2032年には51億9,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは10.0％で成長する見通しです。

帯状疱疹治療薬市場は一貫した成長を遂げており、高齢化社会における帯状疱疹の有病率の増加が主な要因となっています。予防対策や帯状疱疹後神経痛の管理に関する意識の高まりが、ワクチンや抗ウイルス治療への需要を促進しています。技術革新、特にAIは研究に革命をもたらし、薬剤候補の迅速な同定を容易にし、患者の転帰を向上させています。長期的な免疫力を向上させるワクチンに焦点を当てた臨床試験は、特にヘルスケアへのアクセスが改善した発展途上地域で増加傾向にあります。しかし、帯状疱疹の罹患率が増加しているにもかかわらず、積極的に開発を進めている企業は少なく、新規治療薬のパイプラインは依然として限られています。持続的な有効性と副作用の軽減が評価されている遺伝子組換え帯状疱疹ワクチンの採用も、市場の勢いにプラスに寄与しています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

帯状疱疹治療薬市場規模：診断別& CAGR（2025-2032）

• 市場概要
• 臨床検査
• 免疫蛍光顕微鏡検査
• リアルタイムポリメラーゼ連鎖反応（PCR）
• 血清学的検査
• その他

帯状疱疹治療薬市場規模：治療と予防別& CAGR（2025-2032）

• 市場概要
• 抗ウイルス薬
• 麻薬
• 抗炎症薬
• 抗ヒスタミン薬
• 抗けいれん薬
• カプサイシン
• 麻酔クリーム、ジェル、パッチ
• ワクチン
• その他

帯状疱疹治療薬市場規模：投与経路別& CAGR（2025-2032）

• 市場概要
• 経口
• 外用
• その他

帯状疱疹治療薬市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院と診療所
• 診断センター
• 調査・学術機関
• 在宅ケア設定
• その他

帯状疱疹治療薬市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024年）

主要企業プロファイル

• GlaxoSmithKline（GSK）（UK）
• Merck & Co., Inc.（USA）
• Pfizer Inc.（USA）
• Sanofi（France）
• Novartis AG（Switzerland）
• Astellas Pharma Inc.（Japan）
• ModernaTX, Inc.（USA）
• Dynavax Technologies Corporation（USA）
• Curevo, Inc.（USA）
• Jiangsu Recbio Technology Co., Ltd.（China）
• Luzhu Biotechnology Co., Ltd.（China）
• Green Cross Corporation（South Korea）
• BioNTech（Germany）
• Bristol-Myers Squibb（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• SK bioscience（South Korea）
• Vaxine Pty Ltd（Australia）
• EpiVax（USA）
• Virios Therapeutics（USA）
• WEX Pharmaceuticals Inc.（Canada）

結論と提言

Global Herpes Zoster Therapeutics Market size was valued at USD 2.2 billion in 2023 and is poised to grow from USD 2.42 billion in 2024 to USD 5.19 billion by 2032, growing at a CAGR of 10.0% during the forecast period (2025-2032).

The herpes zoster therapeutics market is witnessing consistent growth, largely fueled by the increasing prevalence of shingles in an aging population. A surge in awareness regarding preventive measures and the management of post-herpetic neuralgia is driving demand for vaccines and antiviral treatments. Innovations in technology, particularly AI, are revolutionizing research, facilitating rapid drug candidate identification and enhancing patient outcomes. Clinical trials focused on vaccines that improve long-term immunity are on the rise, especially in developing regions with improved healthcare access. However, the pipeline for new therapies remains limited, with few companies actively pursuing development despite the growing incidence of herpes zoster. The adoption of recombinant zoster vaccines, celebrated for their lasting efficacy and reduced side effects, is also contributing positively to market momentum.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Herpes Zoster Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Herpes Zoster Therapeutics Market Segments Analysis

Global Herpes Zoster Therapeutics Market is segmented by Diagnosis, Treatment and Prevention, Route of Administration, End User and region. Based on Diagnosis, the market is segmented into Laboratory Testing, Immunofluorescent Microscopy, Real-Time Polymerase Chain Reaction (PCR), Serological Testing and Others. Based on Treatment and Prevention, the market is segmented into Antiviral Medications, Narcotic Medications, Anti-Inflammatory Medications, Antihistamines, Anticonvulsants, Capsaicin, Numbing Creams, Gels, or Patches, Vaccines and Others. Based on Route of Administration, the market is segmented into Oral, Topical and Others. Based on End User, the market is segmented into Hospitals & Clinics, Diagnostic Centers, Research & Academic Institutes, Home Care Settings and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Herpes Zoster Therapeutics Market

The Global Herpes Zoster Therapeutics market is being propelled by advancements in Artificial Intelligence, which are enhancing drug discovery processes. Cutting-edge algorithms are adept at sifting through extensive datasets, encompassing genetic, proteomic, and chemical compound libraries, to pinpoint promising antiviral candidates. This innovation significantly lowers both the cost and duration of preclinical and clinical development phases. By 2024, major pharmaceutical companies, such as Pfizer, alongside emerging biotech firms, have adopted AI-driven platforms to expedite research efforts. As a result, this integration is fostering the swift development of next-generation vaccines and treatments for shingles and related complications, including post-herpetic neuralgia (PHN).

Restraints in the Global Herpes Zoster Therapeutics Market

The global market for herpes zoster therapeutics faces significant constraints due to the stringent regulatory frameworks and data privacy issues surrounding the use of patient information for artificial intelligence (AI) algorithm training. In jurisdictions with strict health data protection regulations, such as the General Data Protection Regulation (GDPR) in Europe, the integration of AI in clinical settings is slowed considerably. These regulatory challenges can result in delays for AI-driven innovations, consequently impeding the growth of the market. Consequently, the potential benefits of AI in enhancing herpes zoster therapeutics may be stifled by these compliance-related obstacles.

Market Trends of the Global Herpes Zoster Therapeutics Market

The Global Herpes Zoster Therapeutics market is witnessing a significant trend towards the integration of personalized artificial intelligence (AI) models for preventing post-herpetic neuralgia (PHN), a debilitating complication following shingles. These AI-driven approaches analyze various patient-specific factors, including immune response, genetic predispositions, and individual pain thresholds to formulate customized treatment regimens. By employing real-world data, companies like Tempus and IBM Watson Health are enhancing the efficacy of therapeutic interventions, leading to improved patient outcomes. This trend underscores a shift towards precision medicine, driving growth and innovation in the herpes zoster therapeutics landscape as healthcare evolves to meet personalized patient needs.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Herpes Zoster Therapeutics Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• Laboratory Testing
• Immunofluorescent Microscopy
• Real-Time Polymerase Chain Reaction (PCR)
• Serological Testing
• Others

Global Herpes Zoster Therapeutics Market Size by Treatment and Prevention & CAGR (2025-2032)

• Market Overview
• Antiviral Medications
• Narcotic Medications
• Anti-Inflammatory Medications
• Antihistamines
• Anticonvulsants
• Capsaicin
• Numbing Creams, Gels, or Patches
• Vaccines
• Others

Global Herpes Zoster Therapeutics Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Topical
• Others

Global Herpes Zoster Therapeutics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Diagnostic Centers
• Research & Academic Institutes
• Home Care Settings
• Others

Global Herpes Zoster Therapeutics Market Size & CAGR (2025-2032)

• North America (Diagnosis, Treatment and Prevention, Route of Administration, End User)
  • US
  • Canada
• Europe (Diagnosis, Treatment and Prevention, Route of Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnosis, Treatment and Prevention, Route of Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnosis, Treatment and Prevention, Route of Administration, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnosis, Treatment and Prevention, Route of Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• GlaxoSmithKline (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ModernaTX, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dynavax Technologies Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curevo, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jiangsu Recbio Technology Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Luzhu Biotechnology Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Green Cross Corporation (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SK bioscience (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vaxine Pty Ltd (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EpiVax (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virios Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WEX Pharmaceuticals Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations